---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-071862"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-06-09T20:30:22+00:00"
generated_at: "2026-06-09T20:37:29.040072+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Humacyte shareholders approve increase in authorized shares to 550M at 2026 annual meeting

## Summary
- Authorized common stock raised from 350M to 550M shares; amendment effective June 9, 2026.
- Three Class II directors elected: John Bamforth, Keith Jones, Kathleen Sebelius.
- Say-on-pay passed with 40.1M for, 19.5M against; annual frequency advisory vote adopted.
- Ratification of PwC as auditor for FY 2026 approved with 125.2M for, 1.7M against.
- Quorum of 127.5M shares (~57.4% of outstanding) present at the meeting.

## SEC filing metadata
- accession: 0001104659-26-071862
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-06-09T20:30:22+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/tm2617355d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-071862
- JSON: https://secwatch.observer/filing/0001104659-26-071862.json
- Plain text: https://secwatch.observer/filing/0001104659-26-071862.txt

## Key facts
- Governance Changes
  Humacyte, Inc.: Increased authorized common shares from 350,000,000 to 550,000,000 (effective 2026-06-09).
  - Change: charter amendment
  - Effective: 2026-06-09
  source text: The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 9, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- Shareholder Votes
  Humacyte, Inc. shareholders approved Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2026-06-09 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders approved the Amendment to increase the number of authorized shares of common stock from 350,000,000 shares to 550,000,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- Shareholder Votes
  Humacyte, Inc. shareholders approved Approval of Named Executive Officer Compensation at the 2026-06-09 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as described in the executive compensation section of the proxy statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- Shareholder Votes
  Humacyte, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The appointment of Pricewaterhouse Coopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- Shareholder Votes
  Humacyte, Inc. shareholders approved Election of Class II directors at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders elected each of the three Class II directors who were nominated to serve until the Company’s 2029 annual meeting of stockholders or until such director’s successor is elected, or until such director’s earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm
- Shareholder Votes
  Humacyte, Inc. shareholders approved Approval of the Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2026-06-09 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders approved, on an advisory basis, the holding of advisory vote to approve the compensation paid to the Company’s named executive officers on an annual basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/0001104659-26-071862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.